DSHS | About the King County ICM Pilot Participants

REPORT 4.63

Baseline demographics, health conditions, criminal involvement, and use of alcohol/drug treatment

David Mancuso, Ph.D., Daniel J. Nordlund, Ph.D., Bill Luchansky, Ph.D., Barbara E.M. Felver, M.E.S., M.P.A. In collaboration with the

Health and Recovery Services Administration Division of Alcohol and Substance Abuse



N 2005, the Washington State Legislature passed Senate Bill 5763, a wide-ranging piece of legislation designed to change several aspects of publicly funded substance abuse and mental health treatment in Washington State.

One provision in that legislation created pilot programs to provide intensive case management (ICM) for a target population of persons with histories of high utilization of crisis services coupled with a primary chemical dependency diagnosis or dual primary chemical dependency and mental health diagnosis. The DSHS Division of Alcohol and Substance Abuse (DASA) is responsible for implementing the pilots.

This report provides a preliminary examination of the pilot in King County, which has been in operation since November of 2005. The county contracted with an agency whose primary focus is housing homeless adults with the aim of providing case management services to a select group of their residents. For illustrative purposes, ICM participants are compared with DASA patients who were not participating in ICM but were admitted to alcohol/drug treatment in 2006.

This report focuses on two issues:

- 1. Whether the target population is being served, and
- 2. Whether contracted providers are meeting service expectations.


Key Findings

There are several distinct differences between ICM participants and non-participants:

- Medical costs The King County pilot is successfully targeting patients with high medical risk. Among patients enrolled in feefor-service DSHS medical coverage, medical costs for ICM participants averaged \$2,292 per member per month, compared to \$510 for non-participants. Most of the difference is due to extremely high baseline inpatient acute care costs for ICM participants.
- Arrests The King County pilot is successfully targeting patients who are at increased risk of criminal justice involvement.
- Use of detoxification services ICM participants are more likely than non-participants to have used detox services in the baseline period.
- Use of psychiatric inpatient services ICM participants were more likely than non-participants to have been hospitalized in a community psychiatric facility in the baseline period.
- **Demographic differences ICM** participants were more likely to be older, male, and Native American, and less likely to be African American.

ICM participants have higher PMPM medical costs

FEE-FOR-SERVICE (FFS) patients only



A Context for Intensive Care Management

The Legislation

The goal of SB 5763 was to more fully integrate treatment for mental health and chemical dependency disorders and in the process improve treatment for patients with co-occurring disorders. The ICM pilots play an important role in this integration by: 1) targeting those with co-occurring disorders, 2) using screening and assessment instruments specifically designed for the co-occurring population, and 3) employing case managers who are familiar with the target population. Features of the pilots include:


- Two DASA-selected sites, one in Thurston/Mason and one in King County.
- Specific requirements for chemical dependency case managers, including training in and use of screening and assessment tools. In addition, case managers must assist patients as they seek access to other DSHS services (e.g., medical coverage or economic assistance programs) and work with other providers to insure that patient needs are being met.
- A two-year pilot period. Funds for these programs became effective in July 2005, though the first patients were not served until November of that year. Funding runs through June 2008. Analyses presented here will focus on ICM participants receiving services from startup through December 2006, and comparison patients receiving treatment in 2006.



The King County Pilot

The King County ICM Pilot proposed to serve 75 people annually, with each case manager handling approximately 35 to 40 individuals. Records from DASA's TARGET database show a great deal of variation in the number served per month, ranging from a low of 13 to a high of 33 patients in 2006. TARGET records show that 55 received ICM services in 2006.

ICM Participants Served per Month



TIMEFRAMES

ICM PARTICIPANTS VERSUS NON-PARTICIPANTS – Throughout this report, ICM participants are compared to non-participants, defined as those adults who did not receive ICM services but were admitted to alcohol/drug treatment in King County in 2006.

DEFINING TREATMENT ENTRY – Comparisons of service utilization were done by examining data in the year prior to each patient's **program entry date**.

- For ICM participants, the program entry date is the date in 2006 when they began receiving ICM services. This date is gathered from the TARGET database.
- For non-participants, the program entry date was defined as the date of their first admission to substance abuse treatment in 2006.

For patients in both groups, the **year prior to program entry** is defined as the 12 months prior to the month including the program entry date.

¹ICM funds provide employment for two case managers at the contractor's facility. The contractor employs several case managers, but only two have been designated to enter data into TARGET. If a patient begins receiving services from one of the designated case managers and shifts to another manager's caseload, subsequent services are not being entered into TARGET. This arrangement could account for some of the low monthly counts shown on page 2.


Past Year Measures | All Patients

Arrested in year prior to entry?



Medical coverage in year prior to entry?

DSHS fee-for-service medical



Past Year Differences Between ICM Participants and Non-Participants

Data from the year prior to program entry documents how ICM participants differed from non-participants in the key areas of criminal justice involvement, DSHS medical coverage, and DSHS service utilization.

Three key findings emerge from the data:


- ICM participants were more likely to have an arrest recorded in the Washington State Patrol (WSP) database, 52 percent versus 33 percent for non-participants.
- A higher percentage of ICM participants received fee-for-service DSHS medical coverage in the prior year, 84 percent versus 52 percent. This indicates that ICM participants were more likely to receive medical coverage under the Medicaid Disabled, GA-U or ADATSA programs.
- ICM participants were far more likely to have received detoxification services (63 percent versus 14 percent), but only somewhat more likely to have received alcohol/drug treatment in the prior year (42 percent versus 32 percent).

Demographic data show that ICM participants are significantly older than non-participants, more likely to be Native American, less likely to be African American, and far more likely to be male.

All Patients | Received Alcohol or Substance Abuse Services in Year Prior to Entry


| Services administered by DSHS Division of Alcohol and Substance Abuse | Non-Participants n = 7,617 | ICM Participants <i>n</i> = 64 |
|---|-------------------------------|-----------------------------------|
| Any DASA Service* | 54.4% | 79.7% |
| Any Alcohol or Drug Treatment* | 32.2% | 42.2% |
| Outpatient Treatment | 19.2% | 26.6% |
| Residential Treatment | 14.0% | 31.3% |
| Opiate Substitution Treatment | 7.7% | 0.0% |
| Detoxification | 14.0% | 62.5% |
| Assessment | 42.2% | 39.1% |

*Patients may receive more than one type of service; thus, subcategories will not sum to the overall percentages shown for "Any Alcohol or Drug Treatment" or "Any DASA Service."



Past Year Measures | Fee-for-Service (FFS) Medical Patients

Arrest(s) in year prior to entry?



Received detoxification in year prior to entry?



Past Year Differences Between ICM Participants and Non-Participants

Fee-for-Service (FFS) DSHS Medical patients are an important subgroup in this study because of the availability of additional medical data. Prior year measures for the subset of patients enrolled in fee-for-service medical coverage show very similar results to the comparisons for all patients. Specifically:

- FFS ICM participants were more likely to have a previous arrest,
 50 percent versus 34 percent.
- FFS ICM participants were over 2.5 times more likely to have received detoxification services.
- FFS ICM participants were somewhat more likely to have received alcohol or drug treatment, but less likely to have received an assessment for treatment (43 percent versus 59 percent).


Demographic data show some clear differences between ICM and non-participants:

- 71 percent of FFS ICM participants were 45 years of age or older compared to 34 percent of FFS non-participants.
- Native Americans made up 33 percent of FFS ICM participants but only 6 percent of FFS non-participants.
- About 7 percent of FFS ICM participants were African American, compared to 25 percent of FFS non-participants.

Fee-for-Service | Received DASA Services in Year Prior to Entry

| Services administered by DSHS Division of Alcohol and Substance Abuse | FFS Non-Participants n = 3,952 | FFS ICM Participants $n = 54$ |
|--|-----------------------------------|-------------------------------|
| Any DASA Service* | 73.7% | 77.8% |
| Any Alcohol or Drug Treatment* | 45.9% | 48.2% |
| Outpatient Treatment | 25.3% | 29.6% |
| Residential Treatment | 22.9% | 37.0% |
| Opiate Substitution Treatment | 11.4% | 0.0% |
| Detoxification | 21.6% | 59.3% |
| Assessment | 59.2% | 42.6% |

*Fee-for-service patients may receive more than one type of service; thus, subcategories will not sum to the overall percentages shown for "Any Alcohol or Drug Treatment" or "Any DASA Service."




Medical Eligibility in Year Prior to Entry

Fee-for-service (FFS) ICM participants averaged 8.6 months of medical eligibility in the year prior to program entry, compared to only 7.4 months for FFS non-participants. In most months FFS ICM participants were covered under the Medicaid program for patients with disabilities.


| Average months of medical eligibility | FFS Non-Participants $n = 3,952$ | FFS ICM Participants n = 54 |
|---------------------------------------|----------------------------------|--------------------------------|
| Any DSHS Medical Coverage | 7.43 | 8.64 |
| Medicaid Disabled | 4.26 | 6.17 |
| ADATSA | 1.35 | 0.96 |
| GA-U | 1.25 | 0.74 |
| Medicaid Aged | 0.04 | 0.44 |
| Other Medicaid | 0.38 | 0.00 |
| Other | 0.15 | 0.33 |

DSHS-paid Prescription Medications in Year Prior to Entry

Received prescription medication for heart disease?



Received prescription medication for seizure disorder?



Received prescription medication for psychotic illness/bipolar disorder?



Data from DSHS-paid prescription medication records point to clear differences between FFS ICM participants and FFS non-participants. Differences in prescribed medications suggests that FFS ICM participants are more likely to have several serious medical conditions and mental health conditions, including:

- Heart Disease: FFS ICM participants were about twice as likely to have been prescribed medications for heart disease compared to FFS non-participants (39 percent versus 22 percent).
- **Seizure disorder**: FFS ICM participants were nearly four times as likely as FFS non-participants to have been prescribed medications for a seizure disorder (41 percent versus 11 percent).
- Psychotic/Bipolar: 26 percent of FFS ICM participants received a prescription for a psychotic illness or bipolar disorder, compared to 19 percent of FFS non-participants.

| Major conditions | FFS Non-Participants n = 3,952 | FFS ICM Participants $n = 54$ |
|---------------------------|-----------------------------------|-------------------------------|
| | | |
| Depression Anxiety | 31.3% | 42.6% |
| Cardiac | 21.1% | 38.9% |
| Seizure Disorders | 10.6% | 40.7% |
| Pain | 32.3% | 33.3% |
| Psychotic Illness Bipolar | 18.9% | 25.9% |

Medicaid Management Information System (MMIS) Claims: Mental Illness Diagnoses in Year Prior to Entry

Diagnosis data show that FFS ICM participants were more likely to have a diagnosed mental illness compared to FFS non-participants (37 percent versus 33 percent).

| A diagnosis of mental illness appeared on a medical claim received by DSHS | FFS Non-Participants $n = 3,952$ | FFS ICM Participants n = 54 | |
|--|----------------------------------|--------------------------------|--|
| Any Mental Illness | 32.7% | 37.0% | |
| Schizophrenia | 7.4% | 5.5% 9.2% | |
| Mania/Bipolar | 5.8% | 3.7% | |
| Depression/Personality | 19.5% | 27.8% | |

DSHS Mental Health Division Services in Year Prior to Entry


Over one-third of both groups received publicly funded mental health services in the year prior to entry. Overall, FFS ICM participants were more likely to have received mental health services (48 percent versus 39 percent) and more likely to have received services in a community inpatient hospital (25.9 percent versus 6.5 percent).

| Services administered by DSHS Mental Health Division | FFS Non-Participants $n = 3,952$ | FFS ICM Participants $n = 54$ |
|--|----------------------------------|-------------------------------|
| Any MHD Service* | 39.2% | 48.1% |
| Community Services | 38.3% | 42.6% |
| Community Inpatient | 6.5% | 25.9% |
| State Hospital | 0.9% | 1.9% |

^{*}Patients may receive more than one type of service; thus, subcategories will not sum to the overall percentages for "Any MHD Service."

Medical Assistance Costs in Year Prior to Entry

ICM participants have higher medical costs



On average, FFS ICM participants had publicly funded per-person per-month medical costs of \$2,292, compared to \$510 for FFS non-participants. In addition, FFS ICM participants had higher averages on each component of the overall costs:

- The largest difference in costs between FFS ICM participants and FFS non-participants was for inpatient expenses. FFS ICM participants averaged \$1,665 per month compared to just \$230 for FFS non-participants.
- FFS ICM participants averaged just over \$191 per month in outpatient emergency room costs, compared to \$53 for FFS non-participants.
- Other medical costs, including medications, outpatient services and medical equipment, averaged \$436 for FFS ICM participants and \$227 for FFS non-participants.

| Per member per month expenditures | FFS Non-Participants $n = 3,592$ | FFS ICM Participants n = 54 |
|-----------------------------------|----------------------------------|--------------------------------|
| Total Medical Assistance | \$510 | \$2,292 |
| Inpatient | \$230 | \$1,665 |
| Outpatient ER | \$53 | \$191 |

Summary Remarks

This report focused on the patients in the King County Intensive Case Management project and compared them with other patients receiving publicly funded alcohol/drug treatment in the county. As expected, the data document clear differences between the groups which indicates that the King County pilot is successfully targeting high risk patients:

- ICM participants have extremely high medical costs compared to other patients receiving alcohol/drug treatment.
- ICM participants are more likely to have been recently arrested.
- ICM participants were much more likely to have been detoxed during the baseline period prior to entering the ICM program.
- ICM participants were more likely than non-participants to have been hospitalized in a community psychiatric facility during the baseline period prior to entering the ICM program.

This report was designed with the limited goal of examining how ICM participants differ from non-participants to assess whether the pilot project is reaching its target population. A future report will examine outcomes associated with the receipt of ICM services, including medical and mental health service utilization and criminal justice involvement in the year following program entry.

TECHNICAL NOTES

This report examines the characteristics of patients who received a DASA-funded Intensive Case Management services. The analyses presented in this report used data from the following sources:

- The Research and Data Analysis Division Client Services Database provided patient demographics and a common identifier for linking patient information from multiple data sources. Mental Health Division service data were also obtained through the Client Services Database.
- DASA's TARGET data system provided information on ICM, alcohol/drug treatment, detoxification, and assessment services.
- Medical claims from the Medicaid Management Information System provided: diagnoses of chronic physical conditions and mental illness; information from pharmacy claims; and medical service cost and utilization data. Claims-based reimbursement amounts for acute medical inpatient admissions at hospitals participating in the Certified Public Expenditure (CPE) program were adjusted to reflect the full cost of the inpatient stay.
- OFM Eligibility data provided information on patients' medical coverage.
- Arrest data from the Washington State Patrol (WSP) identified patients who had been arrested. Local law enforcement agencies are generally required to report only felony and gross misdemeanor offenses into the WSP arrest database. This report somewhat understates the full volume of arrest events in the population because our data exclude arrests for an unknown number of misdemeanor offenses that are not required to be reported into this database.

Mental illnesses were identified using the psychiatric diagnosis categories from the Chronic Illness and Disability Payment System (CDPS). Pharmacy claims were classified using the drug classes from the Medicaid-Rx pharmacy-based risk adjustment tool.

APPENDIXA Diagnoses of King County ICM Participants Compared to Non-Participants

| | SAMPLE DIAGNOSES | FFS ICM n=54 | FFS Non- ICM n=3,852 |
|--|---|-----------------|----------------------------|
| BY CDPS DISEASE GROUP | | | |
| Cancer, high | Lung cancer, ovarian cancer, secondary malignant neoplasms | 1.9% | 0.3% |
| Cancer, medium | Mouth, breast or brain cancer, malignant melanoma | 0.0% | 0.4% |
| Cancer, low | Colon, cervical, or prostate cancer, carcinomas in situ | 0.0% | 0.4% |
| Cardiovascular, very high | Heart transplant status/complications | 1.9% | 0.4% |
| Cardiovascular, medium | Congestive heart failure, cardiomyopathy | 11.1% | 2.1% |
| Cardiovascular, low | Endocardial disease, myocardial infarction, angina | 20.4% | 6.3% |
| Cardiovascular, extra low | Hypertension | 13.0% | 9.4% |
| Cerebrovascular, low | Intracerebral hemorrhage, precerebral occlusion | 16.7% | 1.5% |
| CNS, high | Quadriplegia, amyotrophic lateral sclerosis | 0.0% | 0.1% |
| CNS, medium | Paraplegia, muscular dystrophy, multiple sclerosis | 3.7% | 0.5% |
| CNS, low | Epilepsy, Parkinson's disease, cerebral palsy, migrane | 31.5% | 11.2% |
| DD, medium | Severe or profound mental retardation | 0.0% | 0.0% |
| DD, low | Mild or moderate mental retardation, Down's syndrome | 0.0% | 0.2% |
| Diabetes, type 1 high | Type 1 diabetes with renal manifestations/coma | 0.0% | 0.1% |
| Diabetes, type 1 medium | Type 1 diabetes without complications | 0.0% | 1.2% |
| Diabetes, type 2 medium | Type 2 or unspecified diabetes with complications | 1.9% | 0.6% |
| Diabetes, type 2 low | Type 2 or unspecified diabetes w/out complications | 9.3% | 3.3% |
| Eye, low | Retinal detachment, choroidal disorders | 0.0% | 0.3% |
| Eye, very low | Cataract, glaucoma, congenital eye anomaly | 5.6% | 0.6% |
| Genital, extra low | Uterine and pelvic inflammatory disease, endometriosis | 0.0% | 1.5% |
| Gastro, high | Peritonitis, hepatic coma, liver transplant | 3.7% | 0.5% |
| Gastro, medium | Regional enteritis and ulcerative colitis, enterostomy | 22.2% | 3.9% |
| Gastro, low | Ulcer, hernia, GI hemorrhage, intestinal infectious disease | 14.8% | 9.1% |
| Hematological, extra high | Hemophilia | 0.0% | 0.0% |
| Hematological, very high | Hemoglobin-S sickle-cell disease | 0.0% | 0.1% |
| Hematological, medium | Other hereditary hemolytic anemias, aplastic anemia | 5.6% | 1.1% |
| Hematological, low | Other white blood cell disorders, other coagulation defects | 13.0% | 1.7% |
| AIDS, high | AIDS, pneumocystis pneumonia, cryptococcosis | 3.7% | 3.1% |
| HIV, medium | Asymptomatic HIV infection | 0.0% | 0.3% 0.4% |
| Infectious, high Infectious, medium | Staphylococcal or pseudomonas septicemia Other septicemia, pulmonary or disseminated candida | 0.0% 7.4% | 0.4% |
| Infectious, medium Infectious, low | Poliomyelitis, oral candida, herpes zoster | 5.6% | 2.4% |
| Metabolic, high | Panhypopituitarism, pituitary dwarfism | 13.0% | 1.5% |
| Metabolic, medium | Kwashiorkor, merasmus, and other malnutrition, parathyroid | 3.7% | 0.7% |
| Metabolic, medium | Other pituitary disorders, gout | 5.6% | 2.5% |
| Psychiatric, high | Schizophrenia | 5.6% | 7.4% |
| Psychiatric, medium | Bipolar affective disorder | 3.7% | 5.8% |
| Psychiatric, low | Other depression, panic disorder, phobic disorder | 27.8% | 19.6% |
| Pulmonary, very high | Cystic fibrosis, lung transplant, tracheostomy status | 0.0% | 0.0% |
| Pulmonary, high | Respiratory arrest or failure, primary pulmonary hypertension | 7.4% | 1.3% |
| Pulmonary, medium | Other bacterial pneumonias, chronic obstructive asthma | 9.3% | 1.1% |
| Pulmonary, low | Viral pneumonias, chronic bronchitis, asthma, COPD | 29.6% | 13.6% |
| Renal, very high | Chronic renal failure, kidney transplant status/complications | 0.0% | 0.3% |
| Renal, medium | Acute renal failure, chronic nephritis, urinary incontinence | 11.1% | 2.9% |
| Renal, low | Kidney infection, kidney stones, hematuria, urethral stricture | 3.7% | 2.3% |
| Skeletal, medium | Chronic osteomyelitis, aseptic necrosis of bone | 3.7% | 0.4% |
| Skeletal, low | Rheumatoid arthritis, osteomyelitis, systemic lupus | 1.9% | 2.1% |
| Skeletal, very low | Osteoporosis, musculoskeletal anomalies | 3.7% | 4.9% |
| Skeletal, extra low | Osteoarthrosis, skull fractures, other disc disorders | 9.3% | 7.1% |
| Skin, high | Decubitus ulcer | 0.0% | 0.0% |
| Skin, low | Other chronic ulcer of skin | 9.3% | 1.2% |
| Skin, very low | Cellulitis, burn, lupus erythematosus | 27.8% | 15.0% |
| Substance abuse, low | Drug abuse, dependence, or psychosis | 27.8% | 29.6% |
| Substance abuse, very low | Alcohol abuse, dependence, or psychosis | 57.4% | 10.8% |

HOW TO INTERPRET THIS TABLE: Chronic disease conditions were identified by applying the Chronic Illness and Disability Payments System (CDPS) to patients' fee-for-service medical claims in FY 2005. Counts are hierarchically unduplicated within the disease group. For example, a patient with diagnoses of schizophrenia and depression will be counted only once in the "Psychiatric, high" category. Thus, percentages can be added within a disease category (e.g., Psychiatric) to produce the unduplicated percentage of clients in that disease category. Clients with diagnoses in multiple categories (e.g., Cardiovascular and Psychiatric) will be counted once in each broad category represented in their medical claims diagnoses. For more information about the CDPS, see Kronick R, Gilmer T, Dreyfus T, et al. "Improving health-based payment for Medicaid beneficiaries: CDPS," Health Care Fin Rev. 2000; 21:29-64.

APPENDIX B

Drugs Prescribed to King County ICM Participants Compared to Non-Participants

| | SUMMARY DRUG DESCRIPTIONS | FFS ICM n=54 | FFS Non-ICM n=3,852 |
|--------------------------------|--|-----------------|------------------------|
| | | | |
| BY MEDICAID-Rx PHARMACY | | | |
| Alcoholism | Disulfiram | 1.9% | 0.8% |
| Alzheimers | Tacrine | 0.0% | 0.1% |
| Anti-coagulants | Heparins | 9.3% | 1.2% |
| Asthma/COPD | Inhaled glucocorticoids, bronchodilators | 24.1% | 13.5% |
| Attention Deficit | Methylphenidate, CNS stimulants | 0.0% | 0.3% |
| Burns | Silver Sulfadiazine | 5.6% | 0.2% |
| Cardiac | Ace inhibitors, beta blockers, nitrates, digitalis, vasodilators | 38.9% | 22.1% |
| Cystic Fibrosis | Pancrelipase | 0.0% | 0.2% |
| Depression / Anxiety | Antidepressants, antianxiety | 42.6% | 31.3% |
| Diabetes | Insulin, sulfonylureas | 7.4% | 2.8% |
| EENT | Anti-infectives for EENT related conditions | 14.8% | 7.6% |
| ESRD / Renal | Erythropoietin, Calcitriol | 0.0% | 0.1% |
| Folate Deficiency | Folic acid | 11.1% | 1.3% |
| Gallstones | Ursodiol | 0.0% | 0.0% |
| Gastric Acid Disorder | Cimetidine | 16.7% | 6.9% |
| Glaucoma | Carbonic anhydrase inhibitors | 5.6% | 0.3% |
| Gout | Colchicine, Allopurinol | 0.0% | 0.3% |
| Growth Hormone | Growth hormones | 0.0% | 0.0% |
| Hemophilia/von Willebrands | Factor IX concentrates | 0.0% | 0.0% |
| Hepatitis | Interferon beta | 0.0% | 0.0% |
| Herpes | Acyclovir | 0.0% | 1.6% |
| HIV | Antiretrovirals | 0.0% | 0.8% |
| Hyperlipidemia | Antihyperlipidemics | 3.7% | 2.8% |
| Infections, high | Aminogycosides | 0.0% | 0.1% |
| Infections, medium | Vancomycin, Fluoroquinolones | 14.8% | 6.9% |
| Infections, low | Cephalosporins, Erythromycins | 31.5% | 30.6% |
| Inflammatory /Autoimmune | Glucocorticosteroids | 11.1% | 5.8% |
| Insomnia | Sedatives, Hypnotics | 0.0% | 2.1% |
| Iron Deficiency | Iron | 7.4% | 2.2% |
| Irrigating solution | Sodium chloride | 0.0% | 0.2% |
| Liver Disease | Lactulose | 3.7% | 0.6% |
| Malignancies | Antinoeplastics | 0.0% | 0.5% |
| Multiple Sclerosis / Paralysis | Baclofen | 0.0% | 0.6% |
| Nausea | Antiemetics | 11.1% | 8.9% |
| Neurogenic bladder | Oxybutin | 0.0% | 0.4% |
| Osteoperosis / Pagets | Etidronate/calcium regulators | 0.0% | 0.3% |
| Pain | Narcotics | 33.3% | 32.3% |
| Parkinsons / Tremor | Benztropine, Trihexyphenidyl | 1.9% | 2.8% |
| PCP Pneumonia | Pentamidine, Atovaquone | 0.0% | 0.0% |
| Psychotic Illness / Bipolar | Antipsychotics, lithium | 25.9% | 18.9% |
| Replacement solution | Potassium chloride | 11.1% | 2.2% |
| Seizure disorders | Anticonvulsants | 40.7% | 10.6% |
| Thyroid Disorder | Thyroid hormones | 0.0% | 0.4% |
| Transplant | Immunosuppressive agents | 0.0% | 0.1% |
| Tuberculosis | Rifampin | 3.7% | 0.6% |

HOW TO INTERPRET THIS TABLE: Pharmacy groups were identified by applying the Medicaid-Rx system to patients' fee-for-service medical claims in FY 2005. Patients with prescriptions in multiple categories (e.g., Pain and Depression/Anxiety) will be counted in both categories. For more information about the Medicaid-Rx system, see Gilmer T, Kronick R, Fishman P, et al. "The Medicaid Rx Model: Pharmacy-based risk adjustment for public programs," Medicare 2001; 39:1188-1202.

Additional copies of this paper may be obtained from: http://www1.dshs.wa.gov/RDA/ or http://www1.dshs.wa.gov/dasa/ or through the Washington State Alcohol|Drug Clearinghouse by calling 1-800-662-9111 or 206-725-9696 (within Seattle or outside Washington State), by e-mailing clearinghouse@adhl.org, or by writing to 6535 Fifth Place South, Seattle, Washington 98108-0243.

